Alicja Targońska

Alicja Targońska

Auto-generated profile, based on publicly available information

Alicja Targońska

Nencki Institute of Experimental Biology Laboratory of Cytometry Polish Academy of Sciences Warsaw Poland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2025
Verified
Journal Article
Open access
MBMagdalena Bamburowicz-Klimkowska
Magdalena Bamburowicz-Klimkowska
MRMonika Ruzycka-Ayoush
Monika Ruzycka-Ayoush
ATAlicja Targonska
Alicja Targonska
Agnieszka StawarskaAgnieszka Stawarska
Agnieszka Stawarska
IGIreneusz P. Grudzinski
Ireneusz P. Grudzinski
Extracellular vesicles (EVs) secreted by cancer cells play a crucial role in tumor progression by facilitating communication within the tumor microenvironment. These EVs carry molecular payloads that promote cancer cell survival, invasion, and metastasis. Recently, EVs have garnered significant interest as potential drug and gene delivery systems in cancer therapy. Glucose oxidase (GOX) was uploaded into EVs derived from adenocarcinomic human alveolar basal epithelial cells (A549) and further used as a potent starving agent in pristine A549 cells. In uploading studies, various loading methods such as incubation with and without saponin, freeze-thaw cycles, sonication, and different electroporation setups were tested. The electroporation technique exhibited the highest efficiency in loading GOX into EVs while maintaining EV integrity. GOX-loaded A549-derived EVs demonstrated significant cytotoxic effects on pristine A549 cells, suggesting that the EVs could effectively deliver enzymatic cargo to target cancer cells. The results highlight the potential of A549-derived EVs as “Trojan-horse-like” carriers for enzymatic cargo, offering a novel approach for targeting and disrupting metabolic pathways in lung cancer cells. This study presents EVs as promising vehicles for targeted delivery of therapeutic agents in cancer treatment.

1 November 2025 in Nanotechnology, Science and Applications
Verified
Journal Article
Open access
PDF file
SKSwamy Kasarla
Swamy Kasarla
KSKarolina Staniak
Karolina Staniak
MSMagdalena Surman
Magdalena Surman
KZKrystian Zajączkowski
Krystian Zajączkowski
ATAlicja Targońska
Alicja Targońska
TKTomasz Kobiela
Tomasz Kobiela
Purpose: Small extracellular vesicles (sEVs) are nanoscale biomaterial-like structures involved in intercellular communication and cancer progression. Aberrant surface glycosylation may serve as a diagnostic marker for malignancy. This study aimed to compare the size, glycosylation, and biophysical properties of sEVs secreted by primary and metastatic melanoma cells, and to evaluate a novel analytical technique for glycoprofiling. Methods: sEVs were isolated from the primary (WM115) and metastatic (WM266-4) melanoma cell lines. Their size and concentration were assessed via Nanoparticle Tracking Analysis (NTA), and exosomal identity was confirmed using Western blotting. Glycosylation profiling was performed using a multimodal strategy: Quartz Crystal Microbalance with Dissipation monitoring (QCM-D), Nanoplasmonic Sensing (NPS), and, for the first time, Flow-Induced Dispersion Analysis (FIDA). Concanavalin A (Con A) was used as the probe for high-mannose glycans. Results: WM266-4-derived sEVs were significantly larger, whereas WM115 cells secreted more vesicles. Western blotting confirmed the presence of exosomal markers and absence of organelle contaminants. QCM-D and NPS showed stronger Con A binding and higher glycan viscoelasticity index (gVI) in metastatic sEVs, indicating altered glycan architecture. FIDA further confirmed these differences by quantifying a lower dissociation constant (Kd) and multivalent binding behavior in WM266-4-derived sEVs, consistent with a denser glycan coat. Conclusion: Metastatic melanoma–derived sEVs exhibited distinct Con A–detectable high-mannose glycosylation patterns that may represent malignancy-associated features. This study demonstrates the utility of multimodal nanobiophysical methods, particularly FIDA, as sensitive tools for EV glycoprofiling. While the present findings are based on cell line–derived sEVs, they support the translational potential of glycan-based signatures for future liquid biopsy platforms and expand the analytical capabilities of cancer nanodiagnostics. Plain Language Summary: Melanoma is a dangerous type of skin cancer that can spread quickly. Doctors need better ways to tell how aggressive a melanoma is, ideally using simple blood tests. One promising source of information is small extracellular vesicles (sEVs). These nanosized particles are released by all cells, including cancer cells, and carry biological signals that may reveal disease status. In this study, researchers compared sEVs released by two melanoma cell lines: one from an early-stage tumor (WM115) and one from a later, metastatic tumor (WM266-4). Both came from the same patient, making the comparison more reliable. The team found that metastatic cells produced fewer but larger vesicles, with clear differences in the sugar molecules (glycans) displayed on their surfaces. To study these sugar patterns, the researchers combined advanced nanoscale tools: Quartz Crystal Microbalance with Dissipation (QCM-D), NanoPlasmonic Sensing (NPS), and, for the first time in this context, Flow-Induced Dispersion Analysis (FIDA). Using a plant protein called Concanavalin A (Con A), which specifically binds to high-mannose glycans, they showed that vesicles from metastatic cells carried denser and more accessible sugar motifs. These findings suggest that vesicle surface sugars could provide useful clues about melanoma progression. However, the results come from cell line–derived vesicles and have not yet been validated in patient samples. Future studies using broader lectin panels and clinical material will be needed. Even so, this research highlights the potential of glycan signatures and FIDA as part of future non-invasive, nanotechnology-enabled blood tests to monitor cancer.

25 June 2024 in Kosmos
Verified
Journal Article
Open access
PDF file
GMGrazyna Mosieniak
Grazyna Mosieniak
AGAgata Głuchowska
Agata Głuchowska
ATAlicja Targońska
Alicja Targońska
Aging of the organism depends on many factors. One of them is cell senescence, which was first described in the 1960s by Leonard Hayflick, who analyzed fibroblasts cultured in vitro. Further research has shown that cells undergo senescence in the body and, as we age, accumulate in tissues. Senescent cells are characterized by significantly changed morphology, dysfunction of various organelles and altered metabolism. Accordingly, senescent cells acquire new features, that define their role in the aging. One of the most important features of senescent cells is the ability to secrete various types of biologically active factors, that contribute to chronic inflammation and cause tissue and organ dysfunction. Research in recent years has proven that, thanks to pharmacological intervention, it is possible to remove senescent cells from the tissue. This intervention enables to develop new therapeutic strategies aimed at treating age-related diseases and to extent the healthspan of older people.